Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07723118 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Assess the Pharmacokinetics, Safety and Tolerability of Single-dose Adagrasib (BMS-986503) in Healthy Participants of Japanese Descent

StatusCompleted
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary endpoints: details revised at 2 of 7 entries Trial completed · Study completion date changed from estimate of Sep 12, 2026 to Sep 14, 2026 · Eligibility criteria expanded, about 6 words · 1 more Show 4 more changesShow less
    • Trial completed
    • Study completion date changed from estimate of Sep 12, 2026 to Sep 14, 2026
    • Eligibility criteria expanded, about 6 words
    • Study site revised
  2. Recruitment opened Study site revisedv2 Show 1 more changeShow less
    • Study site revised

    See this version in full on ClinicalTrials.gov ↗

  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The aim of this study is to assess the pharmacokinetics, safety and tolerability of single-dose Adagrasib (BMS-986503) in healthy participants of Japanese descent
Trial Details
NCT Number NCT07723118
Lead Sponsor Mirati Therapeutics Inc.
Conditions Healthy Participants
Enrollment 10 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov